Key result
Compared to the poorest 80%, the richest 20% of US adults had lower mean BMI (OR -0.67; 95% CI -0.89 to -0.44), lower systolic blood pressure, and higher HDL.
Why the study?
Disparities in cardiovascular disease prevalence by income have been widening in the US, but the underlying mechanisms and whether similar trends exist in cardiovascular biomarkers remain unclear.
Do cardiovascular disease biomarkers differ between the richest 20% and poorest 80% income groups in the US over time?
Cross-Sectional (n=49,764)
Yes
Do cardiovascular disease biomarkers differ between the richest 20% and poorest 80% income groups in the US over time?
Odds Ratio: -0.67 (95% CI -0.89–-0.44)
Between 1999 and 2018, improvements in cardiovascular disease biomarkers in the US overwhelmingly occurred among the richest 20%, highlighting widening income-based health disparities.
Income-related biomarker gaps may signal need for equity-focused prevention; leaves open underlying drivers and intervention effects.
INTRODUCTION: Income inequality between the richest 20% and the poorest 80% in the United States has been increasing over the past two decades. Emerging evidence indicates widening disparities between the two groups in cardiovascular disease prevalence as well. However, the mechanisms behind this trend remains unclear. This analysis examines whether a similar trend exists in the levels of biomarkers and risk factors of cardiovascular disease in the United States. METHODS: We conducted a serial cross-sectional analysis of a nationally representative data from the National Health and Nutrition Examination Survey (NHANES) for participants age 20 or older between 1999 and 2018. We calculated trends in age-standardized means of body mass index (BMI), systolic blood pressure (SBP), and high-density lipoproteins (HDL) and the trend in prevalence of obesity, high SBP, and low HDL by income group. RESULTS: This analysis included 49,764 participants. Age-standardized mean BMI increased every two years by an average of 0.15 kg/m 2 among the richest 20% and by an average of 0.21 kg/m 2 among the poorest 80%. Age-standardized mean SBP decreased every two years by an average of 0.13 mm Hg among the richest 20% and by an average of 0.10 mm Hg among the poorest 80%. Age-standardized mean HDL increased every two years by an average of 0.39 mg/dL among the richest 20% and by an average of 0.19 mg/dL among the poorest 80%. When adjusted for demographic factors and time, the richest 20% had lower mean BMI (OR = -0.67, 95% CI: -0.89, - 0.44), lower mean SBP (OR = -0.72, 95% CI: -1.24, -0.20), and higher mean HDL (OR = 3.04, 95% CI: 2.46, 3.62) compared to the poorest 80. CONCLUSION: There are increasing disparities in cardiovascular disease biomarkers by income in the US. Between 1999 and 2018, improvement in biomarkers overwhelmingly occurred among the richest 20.
No takes yet. Share an insight, caveat, or question.
Abdalla et al. (2021) conducted a cross-sectional in Cardiovascular disease biomarkers (n=49,764). Richest 20% income group vs. Poorest 80% income group was evaluated on Mean BMI (OR -0.67, 95% CI -0.89, -0.44). Compared to the poorest 80%, the richest 20% of US adults had lower mean BMI (OR -0.67; 95% CI -0.89 to -0.44), lower systolic blood pressure, and higher HDL.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: